TradeFlare's AI research teams analysed SRPT on 12 market nights between March 25, 2026 and September 4, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 4, 2026 | HOLD | $22.99 | — / — | -7.0% | -22.3% | The stock is currently in a neutral market regime and the technicals are not strongly bullish, making it unsuitable for a new buy. |
| September 3, 2026 | HOLD | $23.21 | — / — | -11.1% | -23.9% | The current setup does not warrant a buy. |
| September 2, 2026 | HOLD | $21.33 | — / — | -11.6% | -24.3% | Positive clinical trial data for Duchenne Muscular Dystrophy (DMD) therapies. |
| September 1, 2026 | HOLD | $21.03 | — / — | +3.2% | -14.6% | Post-earnings drift signal from scanner. |
| May 13, 2026 | HOLD | $19.13 | — / — | -9.1% | -20.4% | Continued positive impact from the recent EPS beat and post-earnings drift. |
| May 12, 2026 | BUY | $19.40 | — / — | -13.0% | -21.0% | Continued post-earnings drift (PEAD) following a significant EPS beat. |
| May 11, 2026 | BUY | $19.96 | — / — | -12.3% | -18.1% | Q1 earnings beat and maintained guidance provided a short-term boost. |
| April 28, 2026 | HOLD | $20.98 | — / — | +3.4% | -20.8% | Positive clinical trial data for pipeline assets. |
| April 27, 2026 | HOLD | $20.30 | $21.25 / $17.26 | +5.0% | -20.5% | The current market regime and the stock's neutral technical and fundamental outlook necessitate a wait-and-see approach. |
| April 24, 2026 | HOLD | $20.42 | — / — | +5.9% | -17.2% | Resolution of regulatory concerns surrounding Elevidys. |
| April 23, 2026 | HOLD | $20.64 | — / — | +2.2% | -16.9% | Positive clinical trial data for pipeline candidates. |
| March 25, 2026 | HOLD | — | $41.41 / $21.62 | -6.9% | -14.1% | Q1 2024 Earnings Release on May 2nd |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.